Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.61 |
| ▸ | ALPI | P09923 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | XIAP | P98170 | 1/20 | 0.57 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | ANPEP | P15144 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 3/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
| ▸ | LAP3 | P28838 | 3/20 | 0.48 |
| ▸ | CPA1 | P15085 | 2/20 | 0.48 |
| ▸ | CPB1 | P15086 | 1/20 | 0.48 |
| ▸ | CPA3 | P15088 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346982 | 1.00 | EPHX1 (0.61) | EPHX1ALPIPKMPTGS1XIAP | |
| SCHEMBL7346978 | 1.00 | EPHX1 (0.61) | EPHX1ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL28589045 | 0.98 | EPHX1 (0.59) | EPHX1ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL28589046 | 0.98 | EPHX1 (0.59) | EPHX1ALPIPKMPTGS1XIAP | |
| Acetic Acid SCHEMBL6692778 | 0.94 | ALPI (0.56) | EPHX1ALPIPKMPTGS1XIAP | |
| SCHEMBL8935463 | 0.93 | EPHX1 (0.53) | EPHX1ALPIPKMPTGS1XIAP | |
| SCHEMBL123055 | 0.86 | EPHX1 (0.64) | EPHX1ALPIPKMPTGS1XIAP | |
| SCHEMBL197907 | 0.86 | EPHX1 (0.64) | EPHX1ALPIPKMPTGS1XIAP | |
| SCHEMBL287736 | 0.86 | EPHX1 (0.64) | EPHX1ALPIPKMPTGS1XIAP | |
| SCHEMBL17079480 | 0.85 | MAPT (0.49) | EPHX1ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287251-B2 | Pyrazole derivative or pharmaceutically acceptable salt thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2019-05-14 | — | — | US | disclosed |
| US-20180170879-A1 | PYRAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2018-06-21 | — | — | US | disclosed |
| US-20180170879-A1 | PYRAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2018-06-21 | — | — | US | disclosed |
| WO-2011092671-A1 | PROLINE DERIVATIVES FOR USE IN THE TREATMENT OF DIABETES | RANBAXY LABORATORIES LIMITED (IN) | 2011-08-04 | — | — | WO | disclosed |
| WO-2004085661-A2 | PROCESS TO CHIRAL BETA-AMINO ACID DERIVATIVES | MERCK & CO., INC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287251-B2 | Pyrazole derivative or pharmaceutically acceptable salt thereof | TRPM8, HCN3, HCN4 | EPHX1 4037/4885ALPI 3469/4885PKM 1967/4885 |
| US-20180170879-A1 | PYRAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TRPM8, HCN3, HCN4 | EPHX1 4033/4885ALPI 3128/4885PKM 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.